Skip Nav Destination
Close Modal
Update search
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Article Type
Date
Availability
1-7 of 7
Keywords: elafin
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Articles
Marie-Louise Zani, Annabelle Tanga, Ahlame Saidi, Hélène Serrano, Sandrine Dallet-Choisy, Kévin Baranger, Thierry Moreau
Journal:
Biochemical Society Transactions
Biochem Soc Trans (2011) 39 (5): 1441–1446.
Published: 21 September 2011
... disorders of the lungs. Two unglycosylated natural protease inhibitors, SLPI (secretory leucocyte protease inhibitor) and elafin, and its precursor trappin-2 that are found in the lungs, have therapeutic potential for reducing the protease-induced inflammatory response. This review examines the multifaceted...
Articles
Journal:
Biochemical Society Transactions
Biochem Soc Trans (2011) 39 (5): 1409–1415.
Published: 21 September 2011
... present at mucosal surfaces, have been shown to also possess these characteristic WAP-4-DSC domains. The present review will focus on two WAP-4-DSC containing proteins, namely SLPI (secretory leucocyte protease inhibitor) and trappin-2/elafin. Although first described as antiproteases able to inhibit...
Articles
Journal:
Biochemical Society Transactions
Biochem Soc Trans (2011) 39 (5): 1450–1454.
Published: 21 September 2011
...Lee Shaw; Oliver Wiedow Elafin is an endogenous human protein composed of an N-terminal transglutaminase substrate motif and a C-terminal WAP (whey acidic protein)-domain with antiproteolytic properties. Elafin is expressed predominantly in epithelial tissue and potently inhibits the neutrophil...
Articles
Journal:
Biochemical Society Transactions
Biochem Soc Trans (2011) 39 (5): 1437–1440.
Published: 21 September 2011
...Aaron Scott; Sinéad Weldon; Clifford C. Taggart SLPI (secretory leucoprotease inhibitor) and elafin represent the archetypal members of the WFDC [WAP (whey acidic protein) four disulfide core] family of proteins, and were originally characterized as protease inhibitors but have since been shown...
Articles
Journal:
Biochemical Society Transactions
Biochem Soc Trans (2011) 39 (5): 1427–1432.
Published: 21 September 2011
.... The present review highlights the role and significance of the serine protease inhibitors SLPI (secretory leucocyte protease inhibitor), trappin-2, elafin and ps20 (prostate stromal protein 20 kDa) in HIV susceptibility and infection. Interestingly, in contrast with SLPI, trappin-2 and elafin, ps20 has been...
Articles
Journal:
Biochemical Society Transactions
Biochem Soc Trans (2006) 34 (2): 279–282.
Published: 20 March 2006
..., where they have been shown to have antimicrobial activities, and to activate innate immune responses. This review will address more particularly the pleiotropic functions of low-molecular-mass neutrophil elastase inhibitors [SLPI (secretory leucocyte proteinase inhibitor) and elafin] and, more...
Articles
Journal:
Biochemical Society Transactions
Biochem Soc Trans (2002) 30 (2): 116–120.
Published: 01 April 2002
..., secretory leucocyte proteinase inhibitor and elafin, are presented, with the aim of illustrating their possible involvement in the regulation of inflammation, host defence against infection, tissue repair and extracellular matrix synthesis. 1 e-mail P.S.Hiemstra@lumc.nl 19 12 2001 ©...